[(1S,4R,5R,6R,8R,10S,11R,12S,13R,16R,18S,21R)-8-[(1S)-1,2-dihydroxy-2-methylpropyl]-4,6,12,17,17-pentamethyl-18-[(2S)-4-(oxetan-3-yl)morpholin-2-yl]oxy-9-oxahexacyclo[11.9.0.01,21.04,12.05,10.016,21]docosan-11-yl] N-(2,2,2-trichloroacetyl)carbamate | 1334038-85-5

• 分子结构分类: 有机化合物 - 脂质和类脂质分子
• 英文名称: [(1S,4R,5R,6R,8R,10S,11R,12S,13R,16R,18S,21R)-8-[(1S)-1,2-dihydroxy-2-methylpropyl]-4,6,12,17,17-pentamethyl-18-[(2S)-4-(oxetan-3-yl)morpholin-2-yl]oxy-9-oxahexacyclo[11.9.0.01,21.04,12.05,10.016,21]docosan-11-yl] N-(2,2,2-trichloroacetyl)carbamate
• CAS: 1334038-85-5
• 化学式: C₄₀H₆₁Cl₃N₂O₉
• 分子量: 820.291
• InChiKey: SZBOBKUDSGAXIV-FDOHKDRHSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  7.1
• 重原子数：
  54
• 可旋转键数：
  7
• 环数：
  8.0
• sp3杂化的碳原子比例：
  0.95
• 拓扑面积：
  136
• 氢给体数：
  3
• 氢受体数：
  10

反应信息

• 作为产物：
  描述：

  24-O-acetylhydroshengmanol 3-[beta]-D-xylopyranoside(delta16,17)-enol ether 在 sodium tetrahydroborate 、 lead(IV) tetraacetate 、 氯化锆(IV) 、 sodium cyanoborohydride 、 potassium hydroxide 作用下， 以 四氢呋喃 、 甲醇 、 二氯甲烷 、 乙酸乙酯 为溶剂， 反应 5.0h， 生成 [(1S,4R,5R,6R,8R,10S,11R,12S,13R,16R,18S,21R)-8-[(1S)-1,2-dihydroxy-2-methylpropyl]-4,6,12,17,17-pentamethyl-18-[(2S)-4-(oxetan-3-yl)morpholin-2-yl]oxy-9-oxahexacyclo[11.9.0.01,21.04,12.05,10.016,21]docosan-11-yl] N-(2,2,2-trichloroacetyl)carbamate 、 [(1S)-2-hydroxy-1-[(1S,4R,5R,6R,8R,10S,11R,12S,13R,16R,18S,21R)-11-hydroxy-4,6,12,17,17-pentamethyl-18-[(2S)-4-(oxetan-3-yl)morpholin-2-yl]oxy-9-oxahexacyclo[11.9.0.01,21.04,12.05,10.016,21]docosan-8-yl]-2-methylpropyl] N-(2,2,2-trichloroacetyl)carbamate
  参考文献：
  名称：

  [EN] COMPOUNDS USEFUL FOR TREATING NEURODEGENERATIVE DISORDERS
  [FR] COMPOSÉS UTILES POUR TRAITEMENT DE TROUBLES NEURODÉGÉNÉRATIFS

  摘要：

  本发明提供了式I的化合物：或其药学上可接受的盐，上述列出的每个变量如本文所定义和描述的那样，以及其组合物和使用方法。

  公开号：

  WO2013036684A1

文献信息

• [EN] COMPOUNDS USEFUL FOR TREATING NEURODEGENERATIVE DISORDERS<br/>[FR] COMPOSÉS UTILES POUR LE TRAITEMENT DE TROUBLES NEURODÉGÉNÉRATIFS
  申请人：SATORI PHARMACEUTICALS INC

  公开号：WO2011109657A1

  公开（公告）日：2011-09-09

  As described herein, the present invention provides compounds useful for treating or lessening the severity of a neurodegenerative disorder. The present invention also provides methods of treating or lessening the severity of such disorders wherein said method comprises administering to a patient a compound of the present invention, or composition thereof. Said method is useful for treating or lessening the severity of, for example, Alzheimer's disease.

  如本文所述，本发明提供了用于治疗或减轻神经退行性疾病严重程度的化合物。本发明还提供了治疗或减轻此类疾病严重程度的方法，其中所述方法包括向患者施用本发明的化合物或其组合物。该方法适用于治疗或减轻例如阿尔茨海默病等疾病的严重程度。
• COMPOUNDS USEFUL FOR TREATING NEURODEGENERATIVE DISORDERS
  申请人：Bronk Brian Scott

  公开号：US20110251379A1

  公开（公告）日：2011-10-13

  As described herein, the present invention provides compounds useful for treating or lessening the severity of a neurodegenerative disorder. The present invention also provides methods of treating or lessening the severity of such disorders wherein said method comprises administering to a patient a compound of the present invention, or composition thereof. Said method is useful for treating or lessening the severity of, for example, Alzheimer's disease.